RWLK VS QNCX Stock Comparison

Performance

RWLK
10/100

RWLK returned -33.16% in the last 12 months. Based on SPY's performance of -21.08%, its performance is below average giving it a score of 10 of 100.

QNCX
100/100

QNCX returned 24.64% in the last 12 months. Based on SPY's performance of 9.73%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

RWLK
80/100

5 analysts offer 12-month price targets for RWLK. Together, they have an average target of 3, the most optimistic target put RWLK at 3 within 12-months and the most pessimistic has RWLK at 3.

QNCX

"Analyst Price Targets" not found for QNCX

Sentiment

RWLK
70/100

RWLK had a bullish sentiment score of 69.59% across Twitter and StockTwits over the last 12 months. It had an average of 16.27 posts, 18.18 comments, and 54.60 likes per day.

QNCX

"Sentiment" not found for QNCX

Technicals

RWLK
10/100

RWLK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

QNCX
11/100

QNCX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

RWLK
10/100

RWLK has missed earnings 12 times in the last 20 quarters.

QNCX
10/100

QNCX has missed earnings 5 times in the last 20 quarters.

Profit

RWLK
10/100

Out of the last 20 quarters, RWLK has had 0 profitable quarters and has increased their profits year over year on 0 of them.

QNCX
10/100

Out of the last 20 quarters, QNCX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

RWLK
44/100

RWLK has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

QNCX
46/100

QNCX has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

All score calculations are broken down here to help you make more informed investing decisions

ReWalk Robotics Ltd Summary

Nasdaq / RWLK

Healthcare

Medical Devices

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

Quince Therapeutics, Inc. Common Stock Summary

Nasdaq / QNCX

Healthcare

Biotechnology

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Power up your portfolio